Compare Sirolimus Coated Balloon Catheter With Paclitaxel Coated Balloon Catheter in De Novo Coronary Bifurcated Lesions

NCT04918615 | Unknown DMC

• 1 other identifier: D-IC-040
• Study Type: interventional
• Target: 236
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of Microport sirolimus drug coated balloon catheter for the treatment of coronary bifurcation lesions.

Conditions

Coronary Artery Disease

Keywords

drug coated balloon catheter; coronary bifurcation lesion

Outcome Measures

Primary Outcomes (1)

• Percent Diameter Stenosis (DS) of side branch

  Stenosis of lumen diameter of lesion segment of the side branch

  9 months

Secondary Outcomes (1)

• Late lumen loss (LLL) of side branch

  9 months

Other Outcomes (14)

• Immediate Success Endpoint

  7 days

• DoCE

  30 days, 6 months, 9 months, 12 months, 24 months post-procedure

• PoCE

  30 days, 6 months, 9 months, 12 months, 24 months post-procedure

Study Arms (2)

Sirolimus coated balloon catheter

EXPERIMENTAL

Manufacturer: Shanghai MicroPort Medical Group Co, Ltd.

Procedure: PCI

Paclitaxel coated balloon catheter

ACTIVE COMPARATOR

Manufacturer: Liaoning Yinyi Biotechnology Co., Ltd

Procedure: PCI

Interventions

PCI PROCEDURE

Patients in experimental group will undergo PCI with drug coated balloon catheter to treat the side branch of the coronary bifurcation lesion.

Paclitaxel coated balloon catheter; Sirolimus coated balloon catheter

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or non-pregnant female ages 18-80 years old
• Participants with myocardial ischemia, stable or unstable angina pectoris, old myocardial infarction, or Stabled myocardial infarction (occurred more than 7 days before enrollment, including non-ST elevation and ST elevation myocardial infarction)
• Participants are are eligible to undergo any type of coronary revascularization surgery, such as balloon angioplasty, stenting, and coronary artery bypass grafting (CABG);
• Participants Can understand the trial's purpose, voluntarily participate and acknowledge all the risks and benefits, providing written informed consent and are willing to accept invasive radiographic during the follow-up period.
• Angiography confirmed as De novo bifurcation lesion, the stenosis rate of side branch (diameter) ≥70％
• Suitable for PCI and the side branch lesions is not expected to stent implantation, and no DCB treatment for the main branch. If a stent is implanted into the main-branch, it's usually necessary to perform a final balloon kissing on the two branches
• Up to 2 vessels that need to be treated, total intended treat lesions' amount will not exceed 3
• At most one primary bifurcation lesion that needs treatment (including Medina classification 1.1.1, 1.0.1, 0.1.1), ostium stenosis degree (diameter) ≥70% (visual);
• Patients are suitable for PCI and side branch is not expected to implant a stent, the main branch will not apply drug coated balloon; the main branch will implant a stent, usually the main branch and side branch will have Kissing Balloon Inflation
• The side branch is pre-dilated successfully, no C or upper grade dissection, no tear or other complications occurred, residual stenosis ≤50%, TIMI3
• The reference diameter of the target lesion side branch is 2.0\~4.0 mm, the length of the lesion in side branch is ≤38 mm, and the length of the lesion in main branch is ≤70 mm

You may not qualify if:

• Any AMI occurred within 1 week before operation
• Unstable arrhythmias, such as high-risk ventricular premature beats, ventricular tachycardia
• severe heart failure (above NYHA IV) or Left ventricular ejection fraction (LVEF) \<30% (ultrasound or left ventricular angiography)
• Renal function insufficiency: Serum creatinine \>177μmol/L; Or undergoing hemodialysis;
• definite hemorrhagic tendency, antiplatelet and anticoagulant therapy contraindication and unable to anticoagulant therapy;
• PCI planned within 1 year
• Have a history of peptic ulcer or gastrointestinal hemorrhage in the past 6 months; Have a history of cerebrovascular accidents (stroke) such as cerebral hemorrhage, cerebral infarction in the past 6 months;
• allergic to contrast agent, paclitaxel, and rapamycin and its derivatives
• Has been diagnosed as advanced cancer and other serious diseases, lifespan are expected less than 12 months or hard to complete the 12-month follow up;
• Patients who are considered to have poor compliance and cannot complete the trial in accordance with requirements; Or other reasons that considered by the investigator, it be unsuitable to enroll the participant;
• Be participating in any other clinical trials, or have participated in clinical trials of other drugs or medical devices before being selected but have not reached the timeline of the primary endpoint;
• Female who are pregnant or breastfeeding (women who may become pregnant must undergo a pregnancy test within 7 days before the baseline surgery)；Or have fertility plan/can not have adequate contraception during the study period
• Three vessel disease and all the vessels need revasculization
• Left main and its bifurcation lesions;
• thrombus in the bifurcation lesion, or tortuose lesion that the balloon catheter will not pass through;

Sponsors & Collaborators

• Shanghai MicroPort Medical (Group) Co., Ltd.: lead

Study Sites (1)

General Hospital of the PLA Northern Theater Command

Shengyang, Liaoning, China

Location

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 4, 2021
• First Posted: June 9, 2021
• Study Start: February 28, 2021
• Primary Completion: October 31, 2023
• Study Completion: December 31, 2024
• Last Updated: November 9, 2023

Record last verified: 2023-11

Locations

CN (1)